Generic Name and Formulations:
Brivaracetam 10mg, 25mg, 50mg, 75mg, 100mg; tabs.
Indications for BRIVIACT:
Partial-onset seizures, as monotherapy or adjunctive treatment in patients ≥4yrs.
Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. ≥16yrs: initially 50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily based on response and tolerability. Hepatic impairment: initially 25mg twice daily; max 75mg twice daily. Concomitant rifampin: double brivaracetam dosage.
<4yrs: not established. Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. 4–<16yrs (11–<20kg): initially 0.5–1.25mg/kg twice daily; may adjust down to 0.5mg/kg twice daily or up to 2.5mg/kg twice daily based on response and tolerability; (20–<50kg): initially 0.5–1mg/kg twice daily; may adjust down to 0.5mg/kg twice daily or up to 2mg/kg twice daily; (≥50kg): initially 25–50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily. Hepatic impairment (11–<50kg): initially 0.5mg/kg twice daily; max 2mg/kg twice daily (11–<20kg) or 1.5mg/kg twice daily (20–<50kg); (≥50kg): as Adult. Concomitant rifampin: double brivaracetam dosage.
Increased risk of suicidal behavior or ideation; monitor for clinical worsening and/or any unusual changes. Monitor for neurological and psychiatric adverse reactions. Discontinue if hypersensitivity reactions occur. Hepatic impairment: adjust dose (see Adult). End-stage renal disease undergoing dialysis: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.
Antagonized by rifampin (see Adult). Concomitant carbamazepine: may consider dose reduction if intolerant. May potentiate phenytoin; monitor phenytoin levels when adding or discontinuing brivaracetam from ongoing therapy. Concomitant levetiracetam: no added benefit.
Somnolence/sedation, dizziness, fatigue, nausea/vomiting; hematologic abnormalities.
To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.
Tabs—60; Oral soln—300mL; Single-dose vials—10
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain